



Geisinger Health Plan Policies and Procedure Manual

Policy: MP197

Section: Medical Benefit Policy

Subject: Janus Kinase 2 (JAK 2), CALR and MPL Gene Mutation Analysis

Applicable line of business:

Commercial	x	Medicaid	x
Medicare	x	ACA	x
CHIP	x		

I. Policy: Janus Kinase 2 (JAK 2), CALR and MPL Gene Mutation Analysis

II. Purpose/Objective:

To provide a policy of coverage regarding Janus Kinase 2 (JAK 2), CALR and MPL Gene Mutation Analysis

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children’s Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

Janus Kinase 2 (JAK 2, JAK 2^{V617F}) mutation analysis has been established as a laboratory test to aid in the diagnosis and clinical management and prognosis of patients with primary myelofibrosis (PMF), myeloproliferative disorder (MPD) and myeloproliferative neoplasms (MPN).

The JAK2^{V617F} mutation occurs in exon 14 and is found in greater than 90% of individuals with polycythemia vera, and in nearly 60% of individuals with essential thrombocytopenia (ET) or myelofibrosis (MF). Rare insertions and deletions have been found in exon 12 in 2-3% of patients with polycythemia vera.

Hereditary thrombocytosis has also been reported with germline JAK2 mutation (JAK2 V617I) and associated with vascular events, but not fibrotic/leukemic progression.

Activating mutations in the thrombopoietin receptor gene (MPL) W515L/K) are reported in approximately 5% to 8% of all patients with MF and 1% to 4% of all patients with ET

Frameshift mutations in exon 9 of the calreticulin gene (CALR) are reported in approximately 20% to 35% of all patients with essential ET and MF, which accounts for 60%–80% of patients with JAK2/MPL-negative ET and MF.

Testing of specific variants in JAK2, MPN, and/or MPN has been found to be useful in patients with clinical, laboratory, or pathological findings suggesting essential thrombocytopenia or myelofibrosis and who have tested negative for the V617F mutation in JAK2^{V617F}.

INDICATIONS:

JAK 2^{V617F} mutation analysis is considered medically necessary in the evaluation of:

- Members presenting with clinical, laboratory or pathological findings suggesting classic forms of MPD/MPN/PMF
- Adults, age 21 or older, presenting with clinical, laboratory, or pathological findings suggesting classic forms of polycythemia vera; or
- Adults with isolated idiopathic erythrocytosis, AND a serum erythropoietin level <10.

Testing of additional JAK2 variants (eg, by sequencing) is considered medically necessary in the evaluation and diagnosis of:

- Adult's initial diagnostic evaluation of clinical or laboratory findings suggestive of either:
 - a. essential thrombocytopenia
 - b. primary myelofibrosis

If JAK2 testing is negative, serial testing of MPL followed by CALR is recommended

In members presenting with clinical, laboratory, or pathological findings suggesting classic forms of MPD/MPN/PMF who:

1. were negative for Janus Kinase 2 (JAK2; JAK2^{V617F}) gene mutation
2. testing for variants within JAK2 in exon 12 as well as additional variants CALR and MPL is considered medically necessary.

Additional mutations in ASXL1, EZH2, TET2, IDH1, IDH2, SRSF2, and SF3B1 genes are noted to be of use in determining the clonal nature of disease. In the absence of JAK2, CALR, and MPL mutations, the presence of another clonal marker is included as one of the major diagnostic criteria for PMF and may be considered medically necessary if JAK2, CALR, and MPL testing is negative or inconclusive.

EXCLUSIONS:

Testing for Janus Kinase 2 (JAK 2, JAK 2^{V617F}) gene mutation is considered not medically necessary for any other indication including but not limited to:

- Myeloproliferative disorders (MPD) in children under the age of 21
- Quantitative JAK 2^{V617F} allele burden subsequent to qualitative detection of JAK 2^{V617F}.

Testing for the CALR or MPL gene mutation is considered not medically necessary when the criteria above have not been met.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

CODING ASSOCIATED WITH: Janus Kinase 2 (JAK 2) Gene Mutation Analysis

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

81219 CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9

81270 JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F)
Variant

81279 JAK2 (Janus kinase 2)(eg, myeloproliferative disorder) targeted sequence analysis (eg, exons 12 and 13)

81402 Molecular pathology procedure, Level 3 (eg, > 10 SNP's 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD])
[when specified as the following]:

MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (eg myeloproliferative disorder), common variants (eg, W515A, W515K, W515L, W515R)

81403: Molecular pathology procedure, Level 4 (e.g., analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR [polymerase chain reaction] in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons) - which includes: o JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder), exon 12 sequence and exon 13 sequence, if performed

0017U Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected

0027U JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS: Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WM, the Cancer Genome Project, Green AR. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet* 2005;365:1054-61.

Campbell P, Green, A. The myeloproliferative disorders. *N. Engl. J. Med* 2006; 355:2452-2462.

Campbell PJ, Scott LM, Buck G, Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. *Lancet*. 2005; 366(9501):1945-53.

Jones Av, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G, Lengfelder E, Reiter A, Chase AJ, Cross NC. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. *Blood* 2006;107:3339-3341.

Kiladijian J-J, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon β -2a. *Blood* 2006;108:2037-2040.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK 2 in myeloproliferative disorders. *N engl J med* 2005;352:1779-90.

Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. *Blood* 2006;108:1865-1867.

Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? *Leuk Lymphoma*. 2006; 47(2):177-94.

Tefferi A, Lasho TL, Schwager SM, Strand JS, et al. The clinical phenotype of wild-type, heterozygous and homozygous JAK 2 (V617F) in polycythemia vera. *Cancer* 2006;106:631-5.

Tefferi A, Gilliland DG, Villeval JL, et al. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. *Mayo Clin Proc*. 2005; 80(7):947-58.

Villeval JL, James C, Pisani DF, et al. New insights into the pathogenesis of JAK2V617F positive myeloproliferative disorders and consequences for the management of patients. *Semin Thromb Hemost*. 2006; 32(4):341-51.

Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. *Br J Haematol*. 2005 Oct; 131(2):208-13.

Scott LM, Tong W, Levine RL, et al. JAK2 Exon 12 Mutations in polycythemia vera and idiopathic erythrocytosis. *NEJM* Feb. 2007;356(5):459-468.

Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. *Exp Hematol*. 2007; 35(1):32-38.

Ma W, Kantarjian, Zhang et al. Higher detection rate of JAK 2 mutation using plasma. *Blood* 2008;111(7):3906-3907.

Spivak J, Silver R. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. *Blood*. 2008; 112(2):231-239.

Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia*. 2008; 22(1):14-22.

Ohyashiki K, Kiguchi T, et al. Isolated erythrocythemia: A distinct entity or sub-type of polycythemia vera? *Japanese J Clin Onc*. 2008;38(3):230-232.

Winifred S. Hayes, GTE Report. Janus kinase 2 (JAK2) Sequence Variants (including V617F) for Chronic Myeloproliferative Disorders. May, 2008

Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, and Najfeld V.; BCR-ABL1 Is a Secondary Event Following JAK2V617F in Patients with Polycythemia Vera Who Develop Chronic Myeloid Leukemia; *Blood* 14 Feb 2013

Winifred S. Hayes. GTE Report. Janus kinase 2 (*JAK2*) p.Val617Phe Testing for Myeloproliferative Neoplasms. April 14,2014

Arber D., Orazi A., Hasserjian R., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood*. 2016;127(20):2391-2405

Grinfeld, J., Nangalia, J., Green, A. R. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. *Haematologica*, 2017;102(1), 7-17.

Sokol K, Tremblay D, Bhalla S, et al. Implications of mutation profiling in myeloid malignancies-part 2: myeloproliferative neoplasms and other myeloid malignancies. *Oncology* 2018; 32(5):e45-e51.

Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. *BMC Cancer*. 2019; 19(1):590.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative neoplasms. V3.2024

Kucine N, Chastain KM, Mahler MB, Bussel J. Primary thrombocytosis in children. *Haematologica*. 2014;99(4):620-628.

Ameen M, Siddiqui K, Khan S, et al. Essential Thrombocythemia in Children: A Retrospective Study. *Journal of Hematology, North America*, 10, jun. 2021.

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. PMID: 32974939.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 04/12/07

Revised: 04/08, 4/09 (wording); 4/10 (exclusion added); 3/11 (criteria clarification), 10/13; 10/15 (indication clarification); 9/20 (revise title, add coverage criteria for CALR and MPL); 9/23 (revise criteria); 9/24 (revise criteria)

Reviewed: 3/12, 3/13, 10/14, 10/16, 9/17, 9/18; 9/19, 9/21, 9/22

CMS UM Oversight Committee Approval: 12/23; 11/8/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.